What is Zevra Therapeutics, Inc.'s SG&A?

Zevra Therapeutics, Inc. (ZVRA) reported SG&A of $20.78M in Q1 2026.

How has Zevra Therapeutics, Inc.'s SG&A changed year-over-year?

Zevra Therapeutics, Inc.'s SG&A increased by 6.3% year-over-year, from $19.55M to $20.78M.

What is the long-term trend for Zevra Therapeutics, Inc.'s SG&A?

Over 3 years (2022 to 2025), Zevra Therapeutics, Inc.'s SG&A has grown at a 72.8% compound annual growth rate (CAGR), from $15.04M to $77.62M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Zevra Therapeutics, Inc. ZVRA SG&A

SG&A at other companies

BioMarin PharmaceuticalsBMRN

$258.29M+25.3%

Ultragenyx PharmaceuticalRARE

$88M+1.1%

XER

Xeris Biopharma Holdings, Inc.XERS

$53.14M+20.7%

Theravance BiopharmaTBPH

$17.72M-3.5%

ANI PharmaceuticalsANIP

$73.66M-3.8%

Arrowhead ResearchARWR

——

Segments

By segment

See full

Reportable Segment$14.35M+19.8%

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$773.23M+58.2%

Enterprise value$678.78M+32.5%

P/E6.2×—

P/S6.3×-5.7×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s SG&A?: Zevra Therapeutics, Inc. (ZVRA) reported SG&A of $20.78M in Q1 2026.
How has Zevra Therapeutics, Inc.'s SG&A changed year-over-year?: Zevra Therapeutics, Inc.'s SG&A increased by 6.3% year-over-year, from $19.55M to $20.78M.
What is the long-term trend for Zevra Therapeutics, Inc.'s SG&A?: Over 3 years (2022 to 2025), Zevra Therapeutics, Inc.'s SG&A has grown at a 72.8% compound annual growth rate (CAGR), from $15.04M to $77.62M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.